[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fdxR26goQf-UnwwmZNVvcJSKSBUAXPRBu7smHnOGoFgI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Stony Brook University",[4],190,false,29,10,29634,15,117,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Depression",8,{"name":18,"count":19},"Anxiety",7,{"name":21,"count":22},"Chronic Fatigue Syndrome",6,{"name":24,"count":25},"Multiple Sclerosis",5,{"name":27,"count":28},"Healthy",4,{"name":30,"count":28},"Pain",{"name":32,"count":28},"Breast Cancer",{"name":34,"count":35},"Insulin Resistance",3,[37,42,47,52,57,61,66,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05323175","Erector Spinae Plane (ESP) Block for Renal Colic","2024-06-01","Ropivacaine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04175301","Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.","2026-09-05","Hydrogen",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05245227","Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage","2027-01-01","Sublingual Misoprostol",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06850974","Foley Balloon for Cervical Preparation Before Dilation and Evacuation","2027-03","Misoprostol",{"nctId":58,"briefTitle":59,"date":55,"intervention":60},"NCT06570577","Opioid Sparing Effect of an ISP Nerve Block on Post-Op Pain Control in Posterior Cervical Spine Surgery","Opioids",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04422652","Combination of Novel Therapies for CKD Comorbid Depression","2027-04-01","Bupropion",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05423210","Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme","2027-08","Atezolizumab + FSRT radiation",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06241183","Famotidine and Antacids for Treatment of Dyspepsia","2027-12-31","Intravenous Famotidine",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT07095205","PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.","2029-09-30","Nicotine transdermal patch",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT07076342","The Role of mGluR5 in CBT-I","2030-03-31","PET Scan with [11C]ABP688",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,135,160,178,198,221,239,260,278,300,318,353,375,397,419,440,479,529,558,587,613,631,659,677,703,728,754,772,798,816,848,873,891,909,939,957,975,993,1019,1037,1067,1092,1110,1128,1146,1164,1182,1200,1218,1236,1254,1272,1296,1322,1348,1374,1400,1445,1481,1513,1538,1565,1583,1611,1629,1647,1665,1690,1715,1733,1757,1783,1801,1819,1845,1863,1881,1904,1930,1954,1978,2001,2026,2044,2068,2099,2134,2160,2186,2209,2237,2262,2288,2314,2332,2350,2368,2396,2414,2441,2470,2488,2506,2524,2549],{"intervention":95,"totalTrials":96,"cells":97},"Minocycline",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":117,"NA":133},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":11,"conditions":114,"interventions":116},"NCT03320018","Neuroprotection in Acute Ischemic Stroke","COMPLETED",[89,90],"2019-08-13","2017-08-02",[115],"Stroke, Ischemic",[46,95],{"trials":118,"activeCount":132,"soonestReadout":124},[119],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"NCT06699966","Stony Brook Medicine Anti-Inflammatory Trial","NOT_YET_RECRUITING",[91],"2031-06","2032-01","2027-06",42,[129],"Major Depressive Disorder",[131,95],"Celecoxib",1,{"trials":134,"activeCount":100},[],{"intervention":75,"totalTrials":132,"cells":136},{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":158},{"trials":138,"activeCount":100},[],{"trials":140,"activeCount":100},[],{"trials":142,"activeCount":100},[],{"trials":144,"activeCount":100},[],{"trials":146,"activeCount":132,"soonestReadout":74},[147],{"nctId":72,"briefTitle":73,"status":148,"phases":149,"primaryCompletion":74,"completion":74,"start":150,"enrollment":151,"conditions":152,"interventions":156},"RECRUITING",[91],"2023-11-09",80,[153,154,155],"Dyspepsia","GERD","Acid Reflux",[75,157],"Oral Maalox\u002F Mylanta",{"trials":159,"activeCount":100},[],{"intervention":157,"totalTrials":132,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":176},{"trials":163,"activeCount":100},[],{"trials":165,"activeCount":100},[],{"trials":167,"activeCount":100},[],{"trials":169,"activeCount":100},[],{"trials":171,"activeCount":132,"soonestReadout":74},[172],{"nctId":72,"briefTitle":73,"status":148,"phases":173,"primaryCompletion":74,"completion":74,"start":150,"enrollment":151,"conditions":174,"interventions":175},[91],[153,154,155],[75,157],{"trials":177,"activeCount":100},[],{"intervention":85,"totalTrials":132,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":188,"NA":196},{"trials":181,"activeCount":100},[],{"trials":183,"activeCount":100},[],{"trials":185,"activeCount":100},[],{"trials":187,"activeCount":100},[],{"trials":189,"activeCount":132,"soonestReadout":84},[190],{"nctId":82,"briefTitle":83,"status":148,"phases":191,"primaryCompletion":84,"completion":84,"start":192,"enrollment":127,"conditions":193,"interventions":195},[91],"2025-08-01",[194],"Major Depressive Disorder (MDD)",[85],{"trials":197,"activeCount":100},[],{"intervention":41,"totalTrials":132,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":219},{"trials":201,"activeCount":100},[],{"trials":203,"activeCount":100},[],{"trials":205,"activeCount":100},[],{"trials":207,"activeCount":100},[],{"trials":209,"activeCount":132,"soonestReadout":40},[210],{"nctId":38,"briefTitle":39,"status":211,"phases":212,"primaryCompletion":40,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"ACTIVE_NOT_RECRUITING",[91],"2025-06-01","2022-04-25",24,[217],"Renal Colic",[41],{"trials":220,"activeCount":100},[],{"intervention":131,"totalTrials":132,"cells":222},{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":229,"PHASE4":231,"NA":237},{"trials":224,"activeCount":100},[],{"trials":226,"activeCount":100},[],{"trials":228,"activeCount":100},[],{"trials":230,"activeCount":100},[],{"trials":232,"activeCount":132,"soonestReadout":124},[233],{"nctId":120,"briefTitle":121,"status":122,"phases":234,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":235,"interventions":236},[91],[129],[131,95],{"trials":238,"activeCount":100},[],{"intervention":80,"totalTrials":132,"cells":240},{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":258},{"trials":242,"activeCount":100},[],{"trials":244,"activeCount":100},[],{"trials":246,"activeCount":100},[],{"trials":248,"activeCount":100},[],{"trials":250,"activeCount":132,"soonestReadout":79},[251],{"nctId":77,"briefTitle":78,"status":148,"phases":252,"primaryCompletion":79,"completion":79,"start":253,"enrollment":254,"conditions":255,"interventions":256},[91],"2024-10-03",14,[194],[80,257],"PET Scan with [18F] VAT",{"trials":259,"activeCount":100},[],{"intervention":257,"totalTrials":132,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":276},{"trials":263,"activeCount":100},[],{"trials":265,"activeCount":100},[],{"trials":267,"activeCount":100},[],{"trials":269,"activeCount":100},[],{"trials":271,"activeCount":132,"soonestReadout":79},[272],{"nctId":77,"briefTitle":78,"status":148,"phases":273,"primaryCompletion":79,"completion":79,"start":253,"enrollment":254,"conditions":274,"interventions":275},[91],[194],[80,257],{"trials":277,"activeCount":100},[],{"intervention":51,"totalTrials":132,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":296,"NA":298},{"trials":281,"activeCount":100},[],{"trials":283,"activeCount":100},[],{"trials":285,"activeCount":100},[],{"trials":287,"activeCount":132,"soonestReadout":50},[288],{"nctId":48,"briefTitle":49,"status":148,"phases":289,"primaryCompletion":50,"completion":50,"start":290,"enrollment":291,"conditions":292,"interventions":294},[90],"2025-01-27",1358,[293],"Postpartum Hemorrhage",[51,295],"IV Oxytocin",{"trials":297,"activeCount":100},[],{"trials":299,"activeCount":100},[],{"intervention":295,"totalTrials":132,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":314,"NA":316},{"trials":303,"activeCount":100},[],{"trials":305,"activeCount":100},[],{"trials":307,"activeCount":100},[],{"trials":309,"activeCount":132,"soonestReadout":50},[310],{"nctId":48,"briefTitle":49,"status":148,"phases":311,"primaryCompletion":50,"completion":50,"start":290,"enrollment":291,"conditions":312,"interventions":313},[90],[293],[51,295],{"trials":315,"activeCount":100},[],{"trials":317,"activeCount":100},[],{"intervention":46,"totalTrials":35,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":333,"PHASE4":349,"NA":351},{"trials":321,"activeCount":100},[],{"trials":323,"activeCount":100},[],{"trials":325,"activeCount":132,"soonestReadout":45},[326],{"nctId":43,"briefTitle":44,"status":211,"phases":327,"primaryCompletion":45,"completion":328,"start":329,"enrollment":11,"conditions":330,"interventions":332},[89],"2027-09-30","2019-10-31",[331],"Malignant Glioma",[46],{"trials":334,"activeCount":100},[335,345],{"nctId":336,"briefTitle":337,"status":338,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":96,"conditions":342,"interventions":344},"NCT03971617","Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease","TERMINATED",[89,90],"2021-04-29","2019-05-29",[343],"Parkinson Disease",[46],{"nctId":108,"briefTitle":109,"status":110,"phases":346,"primaryCompletion":112,"completion":112,"start":113,"enrollment":11,"conditions":347,"interventions":348},[89,90],[115],[46,95],{"trials":350,"activeCount":100},[],{"trials":352,"activeCount":100},[],{"intervention":65,"totalTrials":132,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":369,"PHASE4":371,"NA":373},{"trials":356,"activeCount":100},[],{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":132,"soonestReadout":64},[361],{"nctId":62,"briefTitle":63,"status":148,"phases":362,"primaryCompletion":64,"completion":64,"start":363,"enrollment":364,"conditions":365,"interventions":368},[89],"2020-09-24",201,[366,129,367],"Chronic Kidney Diseases","End Stage Kidney Disease (ESRD)",[65],{"trials":370,"activeCount":100},[],{"trials":372,"activeCount":100},[],{"trials":374,"activeCount":100},[],{"intervention":70,"totalTrials":132,"cells":376},{"EARLY_PHASE1":377,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":378,"activeCount":132,"soonestReadout":69},[379],{"nctId":67,"briefTitle":68,"status":148,"phases":380,"primaryCompletion":69,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":386},[87],"2029-08","2022-10-25",12,[385],"Glioblastoma Multiforme",[70],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":100},[],{"trials":392,"activeCount":100},[],{"trials":394,"activeCount":100},[],{"trials":396,"activeCount":100},[],{"intervention":56,"totalTrials":132,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":409},{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":100},[],{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":100},[],{"trials":410,"activeCount":132,"soonestReadout":55},[411],{"nctId":53,"briefTitle":54,"status":148,"phases":412,"primaryCompletion":55,"completion":55,"start":413,"enrollment":414,"conditions":415,"interventions":418},[92],"2025-02-10",102,[416,417],"Abortion, Second Trimester","Abortion, Medical",[56],{"intervention":60,"totalTrials":132,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":422,"activeCount":100},[],{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":100},[],{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":132,"soonestReadout":55},[433],{"nctId":58,"briefTitle":59,"status":148,"phases":434,"primaryCompletion":55,"completion":55,"start":435,"enrollment":436,"conditions":437,"interventions":439},[92],"2025-02-21",60,[438],"Pain, Postoperative",[60],{"intervention":441,"totalTrials":96,"cells":442},"Influenza vaccine",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":461,"PHASE4":463,"NA":477},{"trials":444,"activeCount":100},[],{"trials":446,"activeCount":100},[],{"trials":448,"activeCount":100},[449],{"nctId":450,"briefTitle":451,"status":110,"phases":452,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":460},"NCT03277703","Flu Vaccine Response in Patients on Biologic Therapies",[89],"2020-01-01","2017-11-03",30,[457,458,459],"Rheumatologic Disorder","Inflammatory Bowel Diseases","Immune Complex Diseases",[441],{"trials":462,"activeCount":100},[],{"trials":464,"activeCount":100},[465],{"nctId":466,"briefTitle":467,"status":468,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":476},"NCT01698177","Optimizing Influenza Vaccination in Surgical Oncology Patients","UNKNOWN",[91],"2013-06","2013-07","2011-10",204,[475],"Influenza",[441,441],{"trials":478,"activeCount":100},[],{"intervention":480,"totalTrials":96,"cells":481},"Propofol",{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":527},{"trials":483,"activeCount":100},[],{"trials":485,"activeCount":100},[],{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":100},[],{"trials":491,"activeCount":100},[492,504],{"nctId":493,"briefTitle":494,"status":110,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":502},"NCT03034096","General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial",[91],"2024-09-30","2017-01-31",1826,[500,501],"Anesthesia, General","Surgical Oncology",[480,503],"Volatile Agent",{"nctId":505,"briefTitle":506,"status":110,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":515},"NCT03435003","Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy",[91],"2019-03-30","2019-04-01","2017-08-28",83,[513,514],"Post-operative Nausea and Vomiting","Laparoscopic Sleeve Gastrectomy",[516,517,518,519,520,519,521,522,480,523,524,525,526],"Aprepitant 80 mg Oral","scopolamine transdermal","Dexamethasone","Ondansetron","Reglan","Compazine","Sugammadex","dexmedetomidine","Fentanyl","Sevoflurane","Desflurane",{"trials":528,"activeCount":100},[],{"intervention":518,"totalTrials":96,"cells":530},{"EARLY_PHASE1":531,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":556},{"trials":532,"activeCount":100},[533],{"nctId":534,"briefTitle":535,"status":468,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT05305404","Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol Craving",[87],"2024-06-23","2024-06-30","2022-03-11",70,[542],"Alcohol Use Disorder",[518],{"trials":545,"activeCount":100},[],{"trials":547,"activeCount":100},[],{"trials":549,"activeCount":100},[],{"trials":551,"activeCount":100},[552],{"nctId":505,"briefTitle":506,"status":110,"phases":553,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":554,"interventions":555},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":557,"activeCount":100},[],{"intervention":522,"totalTrials":96,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":585},{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":100},[],{"trials":569,"activeCount":100},[570,574],{"nctId":505,"briefTitle":506,"status":110,"phases":571,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":572,"interventions":573},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"nctId":575,"briefTitle":576,"status":110,"phases":577,"primaryCompletion":578,"completion":579,"start":580,"enrollment":151,"conditions":581,"interventions":583},"NCT02909439","Quality of Recovery After Reversal With Neostigmine or Sugammadex.",[91],"2017-11-09","2018-02","2016-11",[582],"Incomplete Reversal of Neuromuscular Block",[522,584],"Neostigmine",{"trials":586,"activeCount":100},[],{"intervention":588,"totalTrials":132,"cells":589},"Ketones",{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":598,"NA":611},{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":100},[],{"trials":595,"activeCount":100},[],{"trials":597,"activeCount":100},[],{"trials":599,"activeCount":100},[600],{"nctId":601,"briefTitle":602,"status":468,"phases":603,"primaryCompletion":604,"completion":604,"start":605,"enrollment":151,"conditions":606,"interventions":609},"NCT04106882","Dynamic Connectivity Under Metabolic Constraints",[91],"2022-09","2015-06-19",[34,27,607,608],"Diet Modification","Aging",[588,610],"Glucose",{"trials":612,"activeCount":100},[],{"intervention":610,"totalTrials":132,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":623,"NA":629},{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":100},[],{"trials":622,"activeCount":100},[],{"trials":624,"activeCount":100},[625],{"nctId":601,"briefTitle":602,"status":468,"phases":626,"primaryCompletion":604,"completion":604,"start":605,"enrollment":151,"conditions":627,"interventions":628},[91],[34,27,607,608],[588,610],{"trials":630,"activeCount":100},[],{"intervention":632,"totalTrials":132,"cells":633},"Cefadroxil discontinued early",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":657},{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":100},[],{"trials":641,"activeCount":100},[],{"trials":643,"activeCount":100},[644],{"nctId":645,"briefTitle":646,"status":110,"phases":647,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":655},"NCT01244698","Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction",[91],"2014-05","2010-11",132,[652,653,654],"Bacterial Infection","Anti-infective Agents","Breast Implantation",[632,656],"Cefadroxil until drain removal",{"trials":658,"activeCount":100},[],{"intervention":656,"totalTrials":132,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":675},{"trials":662,"activeCount":100},[],{"trials":664,"activeCount":100},[],{"trials":666,"activeCount":100},[],{"trials":668,"activeCount":100},[],{"trials":670,"activeCount":100},[671],{"nctId":645,"briefTitle":646,"status":110,"phases":672,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":673,"interventions":674},[91],[652,653,654],[632,656],{"trials":676,"activeCount":100},[],{"intervention":678,"totalTrials":132,"cells":679},"Morphine",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":701},{"trials":681,"activeCount":100},[],{"trials":683,"activeCount":100},[],{"trials":685,"activeCount":100},[],{"trials":687,"activeCount":100},[],{"trials":689,"activeCount":100},[690],{"nctId":691,"briefTitle":692,"status":468,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT02620631","Study to Examine Pain Relief With Supplemental Intrathecal Morphine in TKA Patients",[91],"2014-02","2017-01","2011-03",54,[699],"Acute Pain",[678],{"trials":702,"activeCount":100},[],{"intervention":704,"totalTrials":132,"cells":705},"risperidone",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":726},{"trials":707,"activeCount":100},[],{"trials":709,"activeCount":100},[],{"trials":711,"activeCount":100},[],{"trials":713,"activeCount":100},[],{"trials":715,"activeCount":100},[716],{"nctId":717,"briefTitle":718,"status":110,"phases":719,"primaryCompletion":720,"completion":721,"start":722,"enrollment":215,"conditions":723,"interventions":725},"NCT00790075","Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children",[91],"2004-06","2004-12","2003-01",[724],"Agitation",[704],{"trials":727,"activeCount":100},[],{"intervention":729,"totalTrials":132,"cells":730},"Bivalirudin",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":752},{"trials":732,"activeCount":100},[],{"trials":734,"activeCount":100},[],{"trials":736,"activeCount":100},[],{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":100},[741],{"nctId":742,"briefTitle":743,"status":338,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT01464671","Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention",[91],"2014-09","2009-07",260,[749],"Coronary Artery Disease",[729,751],"Heparin",{"trials":753,"activeCount":100},[],{"intervention":751,"totalTrials":132,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":770},{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":100},[],{"trials":761,"activeCount":100},[],{"trials":763,"activeCount":100},[],{"trials":765,"activeCount":100},[766],{"nctId":742,"briefTitle":743,"status":338,"phases":767,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":768,"interventions":769},[91],[749],[729,751],{"trials":771,"activeCount":100},[],{"intervention":773,"totalTrials":132,"cells":774},"Buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":796},{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":100},[],{"trials":780,"activeCount":100},[],{"trials":782,"activeCount":100},[],{"trials":784,"activeCount":100},[785],{"nctId":786,"briefTitle":787,"status":788,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":100,"conditions":792,"interventions":794},"NCT03740243","Buprenorphine vs Buprenorphine\u002FNaloxone on the Effects of Maternal Symptomatology","WITHDRAWN",[91],"2020-03-22","2018-11-30",[793],"Opioid-use Disorder",[773,795],"Buprenorphine",{"trials":797,"activeCount":100},[],{"intervention":795,"totalTrials":132,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":814},{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":100},[],{"trials":807,"activeCount":100},[],{"trials":809,"activeCount":100},[810],{"nctId":786,"briefTitle":787,"status":788,"phases":811,"primaryCompletion":790,"completion":790,"start":791,"enrollment":100,"conditions":812,"interventions":813},[91],[793],[773,795],{"trials":815,"activeCount":100},[],{"intervention":817,"totalTrials":132,"cells":818},"Rocuronium",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":827,"NA":846},{"trials":820,"activeCount":100},[],{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":100},[],{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[829],{"nctId":830,"briefTitle":831,"status":110,"phases":832,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":845},"NCT02812186","Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery",[91],"2019-01-17","2019-02-06","2016-12-27",79,[838,839,840,841,842,843,844],"Cholecystitis","Endometriosis","Bowel Obstruction","Fibroids","Prostate Cancer","Chronic Kidney Disease","Uterine Prolapse",[817],{"trials":847,"activeCount":100},[],{"intervention":849,"totalTrials":132,"cells":850},"Transfusion of 7-day stored red blood cells",{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":871},{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":100},[],{"trials":856,"activeCount":100},[],{"trials":858,"activeCount":100},[],{"trials":860,"activeCount":100},[861],{"nctId":862,"briefTitle":863,"status":110,"phases":864,"primaryCompletion":865,"completion":866,"start":695,"enrollment":127,"conditions":867,"interventions":868},"NCT02918851","VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?",[91],"2019-08-09","2019-11-20",[27],[849,869,870],"Transfusion of 28-day stored red blood cells","Transfusion of 42-day stored red blood cells",{"trials":872,"activeCount":100},[],{"intervention":869,"totalTrials":132,"cells":874},{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":883,"NA":889},{"trials":876,"activeCount":100},[],{"trials":878,"activeCount":100},[],{"trials":880,"activeCount":100},[],{"trials":882,"activeCount":100},[],{"trials":884,"activeCount":100},[885],{"nctId":862,"briefTitle":863,"status":110,"phases":886,"primaryCompletion":865,"completion":866,"start":695,"enrollment":127,"conditions":887,"interventions":888},[91],[27],[849,869,870],{"trials":890,"activeCount":100},[],{"intervention":870,"totalTrials":132,"cells":892},{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":901,"NA":907},{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[],{"trials":902,"activeCount":100},[903],{"nctId":862,"briefTitle":863,"status":110,"phases":904,"primaryCompletion":865,"completion":866,"start":695,"enrollment":127,"conditions":905,"interventions":906},[91],[27],[849,869,870],{"trials":908,"activeCount":100},[],{"intervention":910,"totalTrials":132,"cells":911},"Divalproex Sodium",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":937},{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":100},[922],{"nctId":923,"briefTitle":924,"status":110,"phases":925,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":933},"NCT00228046","Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder",[91],"2007-07","2004-01",40,[930,931,932],"Attention Deficit Disorder With Hyperactivity","Conduct Disorder","Oppositional Defiant Disorder",[910,934,935,936],"Methylphenidate","Dextroamphetamine","Mixed Amphetamine Salts",{"trials":938,"activeCount":100},[],{"intervention":935,"totalTrials":132,"cells":940},{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":955},{"trials":942,"activeCount":100},[],{"trials":944,"activeCount":100},[],{"trials":946,"activeCount":100},[],{"trials":948,"activeCount":100},[],{"trials":950,"activeCount":100},[951],{"nctId":923,"briefTitle":924,"status":110,"phases":952,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":953,"interventions":954},[91],[930,931,932],[910,934,935,936],{"trials":956,"activeCount":100},[],{"intervention":936,"totalTrials":132,"cells":958},{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":973},{"trials":960,"activeCount":100},[],{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":100},[],{"trials":966,"activeCount":100},[],{"trials":968,"activeCount":100},[969],{"nctId":923,"briefTitle":924,"status":110,"phases":970,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":971,"interventions":972},[91],[930,931,932],[910,934,935,936],{"trials":974,"activeCount":100},[],{"intervention":503,"totalTrials":132,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":991},{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":100},[],{"trials":984,"activeCount":100},[],{"trials":986,"activeCount":100},[987],{"nctId":493,"briefTitle":494,"status":110,"phases":988,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":989,"interventions":990},[91],[500,501],[480,503],{"trials":992,"activeCount":100},[],{"intervention":994,"totalTrials":132,"cells":995},"StellaLife",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1017},{"trials":997,"activeCount":100},[],{"trials":999,"activeCount":100},[],{"trials":1001,"activeCount":100},[],{"trials":1003,"activeCount":100},[],{"trials":1005,"activeCount":100},[1006],{"nctId":1007,"briefTitle":1008,"status":110,"phases":1009,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":1012,"conditions":1013,"interventions":1015},"NCT07270952","Protocol Efficacy of Mouthwashes in Experimental Gingivitis",[91],"2023-04-19","2023-01-11",34,[1014],"Gingivitis",[994,1016],"Chlorhexidine",{"trials":1018,"activeCount":100},[],{"intervention":1016,"totalTrials":132,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1035},{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":100},[],{"trials":1026,"activeCount":100},[],{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":100},[1031],{"nctId":1007,"briefTitle":1008,"status":110,"phases":1032,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":1012,"conditions":1033,"interventions":1034},[91],[1014],[994,1016],{"trials":1036,"activeCount":100},[],{"intervention":1038,"totalTrials":132,"cells":1039},"Vitamin D3",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1048,"NA":1065},{"trials":1041,"activeCount":100},[],{"trials":1043,"activeCount":100},[],{"trials":1045,"activeCount":100},[],{"trials":1047,"activeCount":100},[],{"trials":1049,"activeCount":100},[1050],{"nctId":1051,"briefTitle":1052,"status":468,"phases":1053,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":1057,"conditions":1058,"interventions":1064},"NCT02920593","A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy",[91],"2018-07-31","2019-03-31","2016-10",412,[1059,1060,1061,1062,1063],"Gestational Hypertension","Toxemia","Superimposed Preeclampsia","Eclampsia","HELLP Syndrome",[1038],{"trials":1066,"activeCount":100},[],{"intervention":1068,"totalTrials":132,"cells":1069},"Oxytocin bolus or oxytocin",{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1090},{"trials":1071,"activeCount":100},[],{"trials":1073,"activeCount":100},[],{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":100},[1080],{"nctId":1081,"briefTitle":1082,"status":468,"phases":1083,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1089},"NCT05236985","Oxytocin Bolus Versus Infusion in Elective Cesarean Section\"",[91],"2024-12-15","2022-03-15",120,[1088],"Elective Cesarean Section",[1068],{"trials":1091,"activeCount":100},[],{"intervention":516,"totalTrials":132,"cells":1093},{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1108},{"trials":1095,"activeCount":100},[],{"trials":1097,"activeCount":100},[],{"trials":1099,"activeCount":100},[],{"trials":1101,"activeCount":100},[],{"trials":1103,"activeCount":100},[1104],{"nctId":505,"briefTitle":506,"status":110,"phases":1105,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1106,"interventions":1107},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1109,"activeCount":100},[],{"intervention":517,"totalTrials":132,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1120,"NA":1126},{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":100},[],{"trials":1121,"activeCount":100},[1122],{"nctId":505,"briefTitle":506,"status":110,"phases":1123,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1124,"interventions":1125},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1127,"activeCount":100},[],{"intervention":519,"totalTrials":132,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1138,"NA":1144},{"trials":1131,"activeCount":100},[],{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":100},[],{"trials":1139,"activeCount":100},[1140],{"nctId":505,"briefTitle":506,"status":110,"phases":1141,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1142,"interventions":1143},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1145,"activeCount":100},[],{"intervention":520,"totalTrials":132,"cells":1147},{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1154,"PHASE4":1156,"NA":1162},{"trials":1149,"activeCount":100},[],{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":100},[],{"trials":1155,"activeCount":100},[],{"trials":1157,"activeCount":100},[1158],{"nctId":505,"briefTitle":506,"status":110,"phases":1159,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1160,"interventions":1161},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1163,"activeCount":100},[],{"intervention":521,"totalTrials":132,"cells":1165},{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1174,"NA":1180},{"trials":1167,"activeCount":100},[],{"trials":1169,"activeCount":100},[],{"trials":1171,"activeCount":100},[],{"trials":1173,"activeCount":100},[],{"trials":1175,"activeCount":100},[1176],{"nctId":505,"briefTitle":506,"status":110,"phases":1177,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1178,"interventions":1179},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1181,"activeCount":100},[],{"intervention":523,"totalTrials":132,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1198},{"trials":1185,"activeCount":100},[],{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[1194],{"nctId":505,"briefTitle":506,"status":110,"phases":1195,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1196,"interventions":1197},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1199,"activeCount":100},[],{"intervention":524,"totalTrials":132,"cells":1201},{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1216},{"trials":1203,"activeCount":100},[],{"trials":1205,"activeCount":100},[],{"trials":1207,"activeCount":100},[],{"trials":1209,"activeCount":100},[],{"trials":1211,"activeCount":100},[1212],{"nctId":505,"briefTitle":506,"status":110,"phases":1213,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1214,"interventions":1215},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1217,"activeCount":100},[],{"intervention":525,"totalTrials":132,"cells":1219},{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1226,"PHASE4":1228,"NA":1234},{"trials":1221,"activeCount":100},[],{"trials":1223,"activeCount":100},[],{"trials":1225,"activeCount":100},[],{"trials":1227,"activeCount":100},[],{"trials":1229,"activeCount":100},[1230],{"nctId":505,"briefTitle":506,"status":110,"phases":1231,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1232,"interventions":1233},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1235,"activeCount":100},[],{"intervention":526,"totalTrials":132,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1252},{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[1248],{"nctId":505,"briefTitle":506,"status":110,"phases":1249,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":1250,"interventions":1251},[91],[513,514],[516,517,518,519,520,519,521,522,480,523,524,525,526],{"trials":1253,"activeCount":100},[],{"intervention":584,"totalTrials":132,"cells":1255},{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1270},{"trials":1257,"activeCount":100},[],{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[],{"trials":1265,"activeCount":100},[1266],{"nctId":575,"briefTitle":576,"status":110,"phases":1267,"primaryCompletion":578,"completion":579,"start":580,"enrollment":151,"conditions":1268,"interventions":1269},[91],[582],[522,584],{"trials":1271,"activeCount":100},[],{"intervention":1273,"totalTrials":132,"cells":1274},"Escitalopram",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1281,"PHASE4":1283,"NA":1294},{"trials":1276,"activeCount":100},[],{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[1285],{"nctId":1286,"briefTitle":1287,"status":110,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1293},"NCT02623205","Advancing Personalized Antidepressant Treatment Using PET\u002FMRI",[91],"2020-03","2015-05",85,[15],[1273],{"trials":1295,"activeCount":100},[],{"intervention":1297,"totalTrials":132,"cells":1298},"Celecoxib 400 mg",{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1320},{"trials":1300,"activeCount":100},[],{"trials":1302,"activeCount":100},[],{"trials":1304,"activeCount":100},[],{"trials":1306,"activeCount":100},[],{"trials":1308,"activeCount":100},[1309],{"nctId":1310,"briefTitle":1311,"status":110,"phases":1312,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1319},"NCT04814355","The Effect of Celecoxib on Neuroinflammation in MDD",[91],"2025-08-11","2026-02-28","2018-08-01",41,[129,1318],"Neuroinflammation",[1297],{"trials":1321,"activeCount":100},[],{"intervention":1323,"totalTrials":132,"cells":1324},"collagenase clostridium histolyticum",{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1344,"NA":1346},{"trials":1326,"activeCount":100},[],{"trials":1328,"activeCount":100},[],{"trials":1330,"activeCount":100},[],{"trials":1332,"activeCount":100},[1333],{"nctId":1334,"briefTitle":1335,"status":110,"phases":1336,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1343},"NCT00260429","Collagenase in the Treatment of Dupuytrens Disease",[90],"2005-08","2008-04","2003-06",38,[1342],"Dupuytren's Disease",[1323],{"trials":1345,"activeCount":100},[],{"trials":1347,"activeCount":100},[],{"intervention":1349,"totalTrials":132,"cells":1350},"Dexmedetomidine Hydrochloride",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1370,"NA":1372},{"trials":1352,"activeCount":100},[],{"trials":1354,"activeCount":100},[],{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":100},[1359],{"nctId":1360,"briefTitle":1361,"status":338,"phases":1362,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1369},"NCT04042727","Controlling Rapid Atrial Fibrillation With Dexmedetomidine",[89,90],"2021-12-31","2019-08-21",13,[1367,1368],"Rapid Atrial Fibrillation","Heart Rate Control",[1349],{"trials":1371,"activeCount":100},[],{"trials":1373,"activeCount":100},[],{"intervention":1375,"totalTrials":132,"cells":1376},"Colchicine 0.6 mg",{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1383,"PHASE4":1396,"NA":1398},{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[],{"trials":1384,"activeCount":100},[1385],{"nctId":1386,"briefTitle":1387,"status":468,"phases":1388,"primaryCompletion":1389,"completion":1390,"start":1391,"enrollment":1392,"conditions":1393,"interventions":1395},"NCT05459974","Use of Colchicine to Decrease Atrial Fibrillation Recurrence After Ablation",[90],"2023-11-30","2024-11-30","2022-06-20",224,[1394],"Atrial Fibrillation",[1375],{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":100},[],{"intervention":1401,"totalTrials":35,"cells":1402},"Collagenase",{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[],{"trials":1408,"activeCount":100},[1409,1420,1430],{"nctId":1410,"briefTitle":1411,"status":468,"phases":1412,"primaryCompletion":694,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1418},"NCT00261144","Collagenase in the Treatment of Cellulite",[89],"2014-03","2013-02",20,[1417],"Cellulite",[1401,1419],"Biological",{"nctId":1421,"briefTitle":1422,"status":788,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":100,"conditions":1426,"interventions":1429},"NCT00261196","Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)",[89],"2009-01","2006-01",[1427,1428],"Adhesive Capsulitis","Frozen Shoulder",[1401],{"nctId":1431,"briefTitle":1432,"status":110,"phases":1433,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":35,"conditions":1436,"interventions":1438},"NCT00261209","Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand",[88,89],"2008-01","2005-01",[1437],"Adhesion of Flexor Tendon of Hand",[1401,1401],{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[],{"trials":1444,"activeCount":100},[],{"intervention":1446,"totalTrials":96,"cells":1447},"Ibuprofen",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1449,"activeCount":100},[],{"trials":1451,"activeCount":100},[],{"trials":1453,"activeCount":100},[1454,1465],{"nctId":1455,"briefTitle":1456,"status":110,"phases":1457,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1461,"interventions":1462},"NCT01827475","Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting",[89],"2011-07","2010-07",90,[30],[1446,1463,1464],"Acetaminophen","Ibuprofen-acetaminophen combination",{"nctId":1466,"briefTitle":1467,"status":110,"phases":1468,"primaryCompletion":927,"completion":927,"start":722,"enrollment":1469,"conditions":1470,"interventions":1472},"NCT00790270","Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial",[89],61,[1471],"Cervical Strain",[1473,1446,1474],"Cyclobenzaprine","Ibuprofen plus Cyclobenzaprine",{"trials":1476,"activeCount":100},[],{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":100},[],{"intervention":1482,"totalTrials":96,"cells":1483},"Cyclophosphamide",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1507,"PHASE4":1509,"NA":1511},{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[],{"trials":1489,"activeCount":100},[1490,1499],{"nctId":1491,"briefTitle":1492,"status":788,"phases":1493,"completion":1494,"start":1495,"enrollment":1496,"conditions":1497,"interventions":1498},"NCT00296205","Phase II High-Dose Cyclophosphamide for Multiple Sclerosis",[89],"2006-02","2003-10",25,[24],[1482],{"nctId":1500,"briefTitle":1501,"status":788,"phases":1502,"completion":1503,"start":1495,"enrollment":100,"conditions":1504,"interventions":1506},"NCT01236456","High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy",[89],"2006-11",[1505],"Chronic Inflammatory Demyelinating Polyneuropathy",[1482],{"trials":1508,"activeCount":100},[],{"trials":1510,"activeCount":100},[],{"trials":1512,"activeCount":100},[],{"intervention":1514,"totalTrials":132,"cells":1515},"Guanfacine XR 3mgs\u002Fdaily",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1517,"activeCount":100},[],{"trials":1519,"activeCount":100},[],{"trials":1521,"activeCount":100},[1522],{"nctId":1523,"briefTitle":1524,"status":110,"phases":1525,"primaryCompletion":1526,"completion":1526,"start":1527,"enrollment":1528,"conditions":1529,"interventions":1531},"NCT03137082","Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)",[88,89],"2021-03-31","2017-07-12",32,[1530],"Alcohol Abstinence",[1514],{"trials":1533,"activeCount":100},[],{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":100},[],{"intervention":1539,"totalTrials":132,"cells":1540},"Convalescent Plasma",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[1547],{"nctId":1548,"briefTitle":1549,"status":338,"phases":1550,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":1555,"interventions":1557},"NCT04344535","Convalescent Plasma vs. Standard Plasma for COVID-19",[88,89],"2021-01-01","2021-02-01","2020-04-08",82,[1556],"COVID",[1539,1558],"Standard Donor Plasma",{"trials":1560,"activeCount":100},[],{"trials":1562,"activeCount":100},[],{"trials":1564,"activeCount":100},[],{"intervention":1558,"totalTrials":132,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1568,"activeCount":100},[],{"trials":1570,"activeCount":100},[],{"trials":1572,"activeCount":100},[1573],{"nctId":1548,"briefTitle":1549,"status":338,"phases":1574,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":1575,"interventions":1576},[88,89],[1556],[1539,1558],{"trials":1578,"activeCount":100},[],{"trials":1580,"activeCount":100},[],{"trials":1582,"activeCount":100},[],{"intervention":1584,"totalTrials":132,"cells":1585},"Sulindac",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1587,"activeCount":100},[],{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":100},[1592],{"nctId":1593,"briefTitle":1594,"status":110,"phases":1595,"primaryCompletion":1596,"completion":1597,"start":1598,"enrollment":1599,"conditions":1600,"interventions":1604},"NCT01761877","NSAID Effects on Clinical and Imaging Breast Biomarkers",[89],"2019-02-07","2019-03-11","2012-12",114,[1601,1602,30,1603],"Inflammation","Cancer","Hypertension",[1584],{"trials":1606,"activeCount":100},[],{"trials":1608,"activeCount":100},[],{"trials":1610,"activeCount":100},[],{"intervention":1463,"totalTrials":132,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1614,"activeCount":100},[],{"trials":1616,"activeCount":100},[],{"trials":1618,"activeCount":100},[1619],{"nctId":1455,"briefTitle":1456,"status":110,"phases":1620,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1621,"interventions":1622},[89],[30],[1446,1463,1464],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"intervention":1464,"totalTrials":132,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1632,"activeCount":100},[],{"trials":1634,"activeCount":100},[],{"trials":1636,"activeCount":100},[1637],{"nctId":1455,"briefTitle":1456,"status":110,"phases":1638,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1639,"interventions":1640},[89],[30],[1446,1463,1464],{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"trials":1646,"activeCount":100},[],{"intervention":1419,"totalTrials":132,"cells":1648},{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1659,"PHASE4":1661,"NA":1663},{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"trials":1654,"activeCount":100},[1655],{"nctId":1410,"briefTitle":1411,"status":468,"phases":1656,"primaryCompletion":694,"completion":1413,"start":1414,"enrollment":1415,"conditions":1657,"interventions":1658},[89],[1417],[1401,1419],{"trials":1660,"activeCount":100},[],{"trials":1662,"activeCount":100},[],{"trials":1664,"activeCount":100},[],{"intervention":1666,"totalTrials":132,"cells":1667},"Melatonin and Donepezil",{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1672,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":100},[1674],{"nctId":1675,"briefTitle":1676,"status":338,"phases":1677,"primaryCompletion":1678,"completion":1679,"start":1680,"enrollment":383,"conditions":1681,"interventions":1683},"NCT02487082","Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders",[89],"2020-12-31","2021-01-29","2015-06",[1682],"Autism Spectrum Disorder",[1666],{"trials":1685,"activeCount":100},[],{"trials":1687,"activeCount":100},[],{"trials":1689,"activeCount":100},[],{"intervention":1691,"totalTrials":132,"cells":1692},"Acetaminophen\u002FOxycodone",{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1709,"PHASE4":1711,"NA":1713},{"trials":1694,"activeCount":100},[],{"trials":1696,"activeCount":100},[],{"trials":1698,"activeCount":100},[1699],{"nctId":1700,"briefTitle":1701,"status":338,"phases":1702,"primaryCompletion":1703,"completion":1703,"start":1704,"enrollment":96,"conditions":1705,"interventions":1707},"NCT02862691","Percocet vs. Bupivicaine for Toothaches in the ED",[89],"2017-08-01","2016-08-01",[1706],"Toothache",[1691,1708],"Bupivicaine",{"trials":1710,"activeCount":100},[],{"trials":1712,"activeCount":100},[],{"trials":1714,"activeCount":100},[],{"intervention":1708,"totalTrials":132,"cells":1716},{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[1723],{"nctId":1700,"briefTitle":1701,"status":338,"phases":1724,"primaryCompletion":1703,"completion":1703,"start":1704,"enrollment":96,"conditions":1725,"interventions":1726},[89],[1706],[1691,1708],{"trials":1728,"activeCount":100},[],{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[],{"intervention":1734,"totalTrials":132,"cells":1735},"Hydroxychloroquine",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1737,"activeCount":100},[],{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":100},[1742],{"nctId":1743,"briefTitle":1744,"status":788,"phases":1745,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":100,"conditions":1748,"interventions":1750},"NCT04347889","Preventing COVID-19 in Healthcare Workers With HCQ: A RCT",[89],"2020-12-30","2020-04-20",[1749],"Covid-19",[1734],{"trials":1752,"activeCount":100},[],{"trials":1754,"activeCount":100},[],{"trials":1756,"activeCount":100},[],{"intervention":1758,"totalTrials":132,"cells":1759},"fluorouracil",{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1761,"activeCount":100},[],{"trials":1763,"activeCount":100},[],{"trials":1765,"activeCount":100},[1766],{"nctId":1767,"briefTitle":1768,"status":468,"phases":1769,"start":1770,"enrollment":1771,"conditions":1772,"interventions":1774},"NCT00003001","Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer",[88,89],"1997-04",63,[1773],"Colorectal Cancer",[1758,1775,1776],"gemcitabine hydrochloride","leucovorin calcium",{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"intervention":1775,"totalTrials":132,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":100},[1791],{"nctId":1767,"briefTitle":1768,"status":468,"phases":1792,"start":1770,"enrollment":1771,"conditions":1793,"interventions":1794},[88,89],[1773],[1758,1775,1776],{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":100},[],{"trials":1800,"activeCount":100},[],{"intervention":1776,"totalTrials":132,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[],{"trials":1808,"activeCount":100},[1809],{"nctId":1767,"briefTitle":1768,"status":468,"phases":1810,"start":1770,"enrollment":1771,"conditions":1811,"interventions":1812},[88,89],[1773],[1758,1775,1776],{"trials":1814,"activeCount":100},[],{"trials":1816,"activeCount":100},[],{"trials":1818,"activeCount":100},[],{"intervention":1820,"totalTrials":132,"cells":1821},"aerosolized vancomycin or gentamicin",{"EARLY_PHASE1":1822,"PHASE1":1824,"PHASE2":1826,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1823,"activeCount":100},[],{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[1828],{"nctId":1829,"briefTitle":1830,"status":110,"phases":1831,"completion":1832,"start":1833,"enrollment":151,"conditions":1834,"interventions":1838},"NCT00396578","Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation",[89],"2004-09","2003-08",[1835,1836,1837],"Ventilator Associated Pneumonia","Respiratory Infection","Tracheobronchitis",[1820],{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[],{"trials":1844,"activeCount":100},[],{"intervention":1473,"totalTrials":132,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[1853],{"nctId":1466,"briefTitle":1467,"status":110,"phases":1854,"primaryCompletion":927,"completion":927,"start":722,"enrollment":1469,"conditions":1855,"interventions":1856},[89],[1471],[1473,1446,1474],{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":100},[],{"trials":1862,"activeCount":100},[],{"intervention":1474,"totalTrials":132,"cells":1864},{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1866,"activeCount":100},[],{"trials":1868,"activeCount":100},[],{"trials":1870,"activeCount":100},[1871],{"nctId":1466,"briefTitle":1467,"status":110,"phases":1872,"primaryCompletion":927,"completion":927,"start":722,"enrollment":1469,"conditions":1873,"interventions":1874},[89],[1471],[1473,1446,1474],{"trials":1876,"activeCount":100},[],{"trials":1878,"activeCount":100},[],{"trials":1880,"activeCount":100},[],{"intervention":1882,"totalTrials":132,"cells":1883},"nitric oxide-releasing acetylsalicylic acid derivative",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1885,"activeCount":100},[],{"trials":1887,"activeCount":100},[1888],{"nctId":1889,"briefTitle":1890,"status":110,"phases":1891,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1895},"NCT00331786","Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer",[88],"2006-07",240,[1773],[1882],{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":100},[],{"trials":1903,"activeCount":100},[],{"intervention":1905,"totalTrials":132,"cells":1906},"vasoactive intestinal peptide",{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1922,"PHASE3":1924,"PHASE4":1926,"NA":1928},{"trials":1908,"activeCount":100},[],{"trials":1910,"activeCount":100},[1911],{"nctId":1912,"briefTitle":1913,"status":110,"phases":1914,"start":1915,"enrollment":1916,"conditions":1917,"interventions":1921},"NCT00004494","Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis",[88],"1998-09",18,[1918,1919,1920],"Sepsis","Respiratory Distress Syndrome","Respiratory Distress Syndrome, Adult",[1905],{"trials":1923,"activeCount":100},[],{"trials":1925,"activeCount":100},[],{"trials":1927,"activeCount":100},[],{"trials":1929,"activeCount":100},[],{"intervention":1931,"totalTrials":132,"cells":1932},"recombinant human IGF-1",{"EARLY_PHASE1":1933,"PHASE1":1935,"PHASE2":1946,"PHASE3":1948,"PHASE4":1950,"NA":1952},{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[1937],{"nctId":1938,"briefTitle":1939,"status":338,"phases":1940,"primaryCompletion":1941,"completion":1941,"start":1942,"enrollment":11,"conditions":1943,"interventions":1945},"NCT00566241","IGF-1 Therapy in Patients With Cystic Fibrosis",[88],"2012-06","2008-06",[1944],"Cystic Fibrosis",[1931],{"trials":1947,"activeCount":100},[],{"trials":1949,"activeCount":100},[],{"trials":1951,"activeCount":100},[],{"trials":1953,"activeCount":100},[],{"intervention":1955,"totalTrials":132,"cells":1956},"pioglitazone",{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":100},[1961],{"nctId":1962,"briefTitle":1963,"status":110,"phases":1964,"primaryCompletion":1965,"completion":1965,"start":1966,"enrollment":11,"conditions":1967,"interventions":1969},"NCT00545857","Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus",[88],"2012-05","2002-06",[1968],"Type 1 Diabetes Mellitus",[1955],{"trials":1971,"activeCount":100},[],{"trials":1973,"activeCount":100},[],{"trials":1975,"activeCount":100},[],{"trials":1977,"activeCount":100},[],{"intervention":1979,"totalTrials":132,"cells":1980},"PolyMVA",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1993,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[1985],{"nctId":1986,"briefTitle":1987,"status":110,"phases":1988,"primaryCompletion":1989,"completion":1680,"start":1459,"enrollment":1365,"conditions":1990,"interventions":1992},"NCT01833273","Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA",[88],"2013-10",[1991],"Glioblastoma Multiform (Grade IV Astrocytoma)",[1979],{"trials":1994,"activeCount":100},[],{"trials":1996,"activeCount":100},[],{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"intervention":2002,"totalTrials":132,"cells":2003},"Syntocinon Nasal Spray, 40IU",{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[2008],{"nctId":2009,"briefTitle":2010,"status":110,"phases":2011,"primaryCompletion":1290,"completion":1290,"start":2012,"enrollment":2013,"conditions":2014,"interventions":2016},"NCT01834261","Brain Dynamics of Oxytocin",[88],"2013-04",51,[2015],"Brain Dynamics in Healthy Adults",[2002,2017],"Syntocinon Placebo Formulation, 40IU",{"trials":2019,"activeCount":100},[],{"trials":2021,"activeCount":100},[],{"trials":2023,"activeCount":100},[],{"trials":2025,"activeCount":100},[],{"intervention":2017,"totalTrials":132,"cells":2027},{"EARLY_PHASE1":2028,"PHASE1":2030,"PHASE2":2036,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[2032],{"nctId":2009,"briefTitle":2010,"status":110,"phases":2033,"primaryCompletion":1290,"completion":1290,"start":2012,"enrollment":2013,"conditions":2034,"interventions":2035},[88],[2015],[2002,2017],{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[],{"trials":2043,"activeCount":100},[],{"intervention":2045,"totalTrials":132,"cells":2046},"Combined treatment: Heart rhythm biofeedback plus hydrogen water",{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2060,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2048,"activeCount":100},[],{"trials":2050,"activeCount":100},[2051],{"nctId":2052,"briefTitle":2053,"status":468,"phases":2054,"primaryCompletion":2055,"completion":2055,"start":2056,"enrollment":2057,"conditions":2058,"interventions":2059},"NCT05397626","Biofeedback and Hydrogen Water as Treatments for Chronic Fatigue Syndrome",[88],"2023-05-23","2022-05-23",39,[21],[2045],{"trials":2061,"activeCount":100},[],{"trials":2063,"activeCount":100},[],{"trials":2065,"activeCount":100},[],{"trials":2067,"activeCount":100},[],{"intervention":2069,"totalTrials":132,"cells":2070},"nanoliposomal irinotecan",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2091,"PHASE3":2093,"PHASE4":2095,"NA":2097},{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[2075],{"nctId":2076,"briefTitle":2077,"status":110,"phases":2078,"primaryCompletion":2079,"completion":2080,"start":2081,"enrollment":1916,"conditions":2082,"interventions":2090},"NCT04088786","Phase I Trial HIPEC With Nal-irinotecan",[88],"2021-10-11","2022-04-14","2019-10-22",[2083,2084,2085,2086,1773,2087,2088,2089],"Peritoneal Cancer","Pseudomyxoma Peritonei","Mucinous Adenocarcinoma","Mucinous Tumor","Gastric Cancer","Primary Peritoneal Carcinoma","Mesothelioma",[2069],{"trials":2092,"activeCount":100},[],{"trials":2094,"activeCount":100},[],{"trials":2096,"activeCount":100},[],{"trials":2098,"activeCount":100},[],{"intervention":2100,"totalTrials":96,"cells":2101},"Fecal Microbial Transplantation",{"EARLY_PHASE1":2102,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2103,"activeCount":100},[2104,2114],{"nctId":2105,"briefTitle":2106,"status":110,"phases":2107,"primaryCompletion":2108,"completion":2108,"start":2109,"enrollment":2110,"conditions":2111,"interventions":2113},"NCT03267238","Fecal Microbial Transplantation in Patients With Crohn's Disease",[87],"2022-02-15","2017-06-16",9,[2112],"Crohn Disease",[2100],{"nctId":2115,"briefTitle":2116,"status":110,"phases":2117,"primaryCompletion":2108,"completion":2108,"start":2118,"enrollment":383,"conditions":2119,"interventions":2123},"NCT03268213","Fecal Microbial Transplantation for C. Difficile and\u002For Ulcerative Colitis or Indeterminate Colitis",[87],"2013-11",[2120,2121,2122],"Clostridium Difficile Infection","Ulcerative Colitis","Indeterminate Colitis",[2100],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"trials":2131,"activeCount":100},[],{"trials":2133,"activeCount":100},[],{"intervention":2135,"totalTrials":132,"cells":2136},"vancomycin or gentamicin",{"EARLY_PHASE1":2137,"PHASE1":2150,"PHASE2":2152,"PHASE3":2154,"PHASE4":2156,"NA":2158},{"trials":2138,"activeCount":100},[2139],{"nctId":2140,"briefTitle":2141,"status":110,"phases":2142,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":2145,"conditions":2146,"interventions":2149},"NCT01878643","Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit",[87],"2002-12","2001-12",47,[1836,2147,2148],"Bacterial Resistance","Respiratory Failure",[2135],{"trials":2151,"activeCount":100},[],{"trials":2153,"activeCount":100},[],{"trials":2155,"activeCount":100},[],{"trials":2157,"activeCount":100},[],{"trials":2159,"activeCount":100},[],{"intervention":2161,"totalTrials":132,"cells":2162},"inhaled nitric oxide",{"EARLY_PHASE1":2163,"PHASE1":2176,"PHASE2":2178,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2164,"activeCount":100},[2165],{"nctId":2166,"briefTitle":2167,"status":468,"phases":2168,"primaryCompletion":2169,"completion":2170,"start":2171,"enrollment":2172,"conditions":2173,"interventions":2175},"NCT04134078","Improving Outcomes in Cardiac Arrest With Inhaled Nitric Oxide",[87],"2020-07","2022-07","2016-08",100,[2174],"Cardiac Arrest",[2161],{"trials":2177,"activeCount":100},[],{"trials":2179,"activeCount":100},[],{"trials":2181,"activeCount":100},[],{"trials":2183,"activeCount":100},[],{"trials":2185,"activeCount":100},[],{"intervention":2187,"totalTrials":132,"cells":2188},"[18F]-DCFPyl Ligand",{"EARLY_PHASE1":2189,"PHASE1":2199,"PHASE2":2201,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2190,"activeCount":100},[2191],{"nctId":2192,"briefTitle":2193,"status":110,"phases":2194,"primaryCompletion":2195,"completion":2195,"start":2196,"enrollment":1415,"conditions":2197,"interventions":2198},"NCT04266392","Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand",[87],"2021-10-15","2019-12-16",[842],[2187],{"trials":2200,"activeCount":100},[],{"trials":2202,"activeCount":100},[],{"trials":2204,"activeCount":100},[],{"trials":2206,"activeCount":100},[],{"trials":2208,"activeCount":100},[],{"intervention":934,"totalTrials":96,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2217,"PHASE4":2219,"NA":2225},{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[],{"trials":2220,"activeCount":100},[2221],{"nctId":923,"briefTitle":924,"status":110,"phases":2222,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":2223,"interventions":2224},[91],[930,931,932],[910,934,935,936],{"trials":2226,"activeCount":100},[2227],{"nctId":2228,"briefTitle":2229,"status":110,"phases":2230,"primaryCompletion":720,"completion":2231,"start":2232,"enrollment":2233,"conditions":2234,"interventions":2236},"NCT00441649","Methylphenidate for Treating Children With ADHD and Tourette Syndrome",[92],"2007-01","2000-02",71,[930,2235],"Tourette Syndrome",[934],{"intervention":2238,"totalTrials":132,"cells":2239},"Gileyna",{"EARLY_PHASE1":2240,"PHASE1":2242,"PHASE2":2244,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2241,"activeCount":100},[],{"trials":2243,"activeCount":100},[],{"trials":2245,"activeCount":100},[],{"trials":2247,"activeCount":100},[],{"trials":2249,"activeCount":100},[],{"trials":2251,"activeCount":100},[2252],{"nctId":2253,"briefTitle":2254,"status":110,"phases":2255,"primaryCompletion":745,"completion":2256,"start":2257,"enrollment":1415,"conditions":2258,"interventions":2261},"NCT02141022","Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya",[92],"2015-09","2013-08",[24,2259,2260],"Cognitive Deficits","Gilenya Modifying Therapy for MS",[2238],{"intervention":2263,"totalTrials":132,"cells":2264},"Nicotine",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2273,"NA":2275},{"trials":2266,"activeCount":100},[],{"trials":2268,"activeCount":100},[],{"trials":2270,"activeCount":100},[],{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":100},[2277],{"nctId":2278,"briefTitle":2279,"status":468,"phases":2280,"primaryCompletion":2281,"completion":2282,"start":2256,"enrollment":2283,"conditions":2284,"interventions":2287},"NCT02643914","Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings",[92],"2017-06","2017-12",23,[2285,2286],"Nicotine Addiction","Cigarette Smoking",[2263],{"intervention":2289,"totalTrials":132,"cells":2290},"0.25% bupivicaine will be injected at the study port site prior to incision",{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2297,"PHASE4":2299,"NA":2301},{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":100},[],{"trials":2296,"activeCount":100},[],{"trials":2298,"activeCount":100},[],{"trials":2300,"activeCount":100},[],{"trials":2302,"activeCount":100},[2303],{"nctId":2304,"briefTitle":2305,"status":468,"phases":2306,"primaryCompletion":648,"completion":648,"start":2307,"enrollment":2172,"conditions":2308,"interventions":2310},"NCT01452633","Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During Laparoscopy",[92],"2011-11",[2309],"Post Operative Pain",[2289,2311,2312,2313],"Saline will be injected at the study port site prior to incision","Saline will be in injected into the port site prior to closure","0.25% bupivicaine will be injected into the port site prior to closure",{"intervention":2311,"totalTrials":132,"cells":2315},{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2322,"PHASE4":2324,"NA":2326},{"trials":2317,"activeCount":100},[],{"trials":2319,"activeCount":100},[],{"trials":2321,"activeCount":100},[],{"trials":2323,"activeCount":100},[],{"trials":2325,"activeCount":100},[],{"trials":2327,"activeCount":100},[2328],{"nctId":2304,"briefTitle":2305,"status":468,"phases":2329,"primaryCompletion":648,"completion":648,"start":2307,"enrollment":2172,"conditions":2330,"interventions":2331},[92],[2309],[2289,2311,2312,2313],{"intervention":2312,"totalTrials":132,"cells":2333},{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2338,"PHASE3":2340,"PHASE4":2342,"NA":2344},{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":100},[],{"trials":2339,"activeCount":100},[],{"trials":2341,"activeCount":100},[],{"trials":2343,"activeCount":100},[],{"trials":2345,"activeCount":100},[2346],{"nctId":2304,"briefTitle":2305,"status":468,"phases":2347,"primaryCompletion":648,"completion":648,"start":2307,"enrollment":2172,"conditions":2348,"interventions":2349},[92],[2309],[2289,2311,2312,2313],{"intervention":2313,"totalTrials":132,"cells":2351},{"EARLY_PHASE1":2352,"PHASE1":2354,"PHASE2":2356,"PHASE3":2358,"PHASE4":2360,"NA":2362},{"trials":2353,"activeCount":100},[],{"trials":2355,"activeCount":100},[],{"trials":2357,"activeCount":100},[],{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":100},[],{"trials":2363,"activeCount":100},[2364],{"nctId":2304,"briefTitle":2305,"status":468,"phases":2365,"primaryCompletion":648,"completion":648,"start":2307,"enrollment":2172,"conditions":2366,"interventions":2367},[92],[2309],[2289,2311,2312,2313],{"intervention":2369,"totalTrials":132,"cells":2370},"Lithium",{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2381},{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[2383],{"nctId":2384,"briefTitle":2385,"status":110,"phases":2386,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":2390,"interventions":2394},"NCT01880957","PET and MRI Brain Imaging of Bipolar Disorder",[92],"2017-06-23","2011-11-08",76,[2391,2392,2393],"Bipolar Disorder","Bipolar Depression","Unipolar Depression",[2369,2395],"Lamotrigine",{"intervention":2395,"totalTrials":132,"cells":2397},{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2402,"PHASE3":2404,"PHASE4":2406,"NA":2408},{"trials":2399,"activeCount":100},[],{"trials":2401,"activeCount":100},[],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"trials":2409,"activeCount":100},[2410],{"nctId":2384,"briefTitle":2385,"status":110,"phases":2411,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":2412,"interventions":2413},[92],[2391,2392,2393],[2369,2395],{"intervention":2415,"totalTrials":132,"cells":2416},"Ketamine",{"EARLY_PHASE1":2417,"PHASE1":2419,"PHASE2":2421,"PHASE3":2423,"PHASE4":2425,"NA":2427},{"trials":2418,"activeCount":100},[],{"trials":2420,"activeCount":100},[],{"trials":2422,"activeCount":100},[],{"trials":2424,"activeCount":100},[],{"trials":2426,"activeCount":100},[],{"trials":2428,"activeCount":100},[2429],{"nctId":2430,"briefTitle":2431,"status":338,"phases":2432,"primaryCompletion":2433,"completion":2434,"start":2435,"enrollment":2436,"conditions":2437,"interventions":2440},"NCT06458842","Postoperative Pain Protocol Limiting Narcotics for Laparoscopic Hand-assisted Donor Nephrectomy",[92],"2019-10-05","2019-10-11","2014-05-23",56,[2438,2439],"Narcotic Use","Renal Transplant Donor of Left Kidney",[2415],{"intervention":2442,"totalTrials":132,"cells":2443},"Ferrous sulfate",{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2448,"PHASE3":2450,"PHASE4":2452,"NA":2454},{"trials":2445,"activeCount":100},[],{"trials":2447,"activeCount":100},[],{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":100},[],{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[2456],{"nctId":2457,"briefTitle":2458,"status":110,"phases":2459,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2466},"NCT05423249","Treatment of Non-Anemic Iron Deficiency in Pregnancy",[92],"2024-11-01","2024-11-15","2022-08-12",150,[2465],"Non-anemic Iron Deficiency",[2442,2467,2468,2469],"Prenatal","Docusate Sodium","Ascorbic Acid 500Mg Tab",{"intervention":2467,"totalTrials":132,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2480,"NA":2482},{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"trials":2477,"activeCount":100},[],{"trials":2479,"activeCount":100},[],{"trials":2481,"activeCount":100},[],{"trials":2483,"activeCount":100},[2484],{"nctId":2457,"briefTitle":2458,"status":110,"phases":2485,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2486,"interventions":2487},[92],[2465],[2442,2467,2468,2469],{"intervention":2468,"totalTrials":132,"cells":2489},{"EARLY_PHASE1":2490,"PHASE1":2492,"PHASE2":2494,"PHASE3":2496,"PHASE4":2498,"NA":2500},{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[],{"trials":2495,"activeCount":100},[],{"trials":2497,"activeCount":100},[],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[2502],{"nctId":2457,"briefTitle":2458,"status":110,"phases":2503,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2504,"interventions":2505},[92],[2465],[2442,2467,2468,2469],{"intervention":2469,"totalTrials":132,"cells":2507},{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2516,"NA":2518},{"trials":2509,"activeCount":100},[],{"trials":2511,"activeCount":100},[],{"trials":2513,"activeCount":100},[],{"trials":2515,"activeCount":100},[],{"trials":2517,"activeCount":100},[],{"trials":2519,"activeCount":100},[2520],{"nctId":2457,"briefTitle":2458,"status":110,"phases":2521,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2522,"interventions":2523},[92],[2465],[2442,2467,2468,2469],{"intervention":2525,"totalTrials":132,"cells":2526},"Perampanel",{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2528,"activeCount":100},[],{"trials":2530,"activeCount":100},[],{"trials":2532,"activeCount":100},[],{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[2539],{"nctId":2540,"briefTitle":2541,"status":338,"phases":2542,"primaryCompletion":2543,"completion":2544,"start":2545,"enrollment":383,"conditions":2546,"interventions":2548},"NCT03020797","A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)",[92],"2023-01-31","2023-02-08","2017-01-12",[2547],"Amyotrophic Lateral Sclerosis",[2525],{"intervention":2550,"totalTrials":132,"cells":2551},"transdermal nicotine patch",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2553,"activeCount":100},[],{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[2564],{"nctId":2565,"briefTitle":2566,"status":338,"phases":2567,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":455,"conditions":2571,"interventions":2573},"NCT00790829","Preemptive Use of the Nicotine Patch for Postoperative Pain Relief After Open Abdominal Surgery",[92],"2011-08","2011-12","2007-08",[2572],"Postoperative Pain",[2550]]